In melanoma patients who are also treated with the immune therapy
pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebo.
«The significant improvement in overall survival with pembrolizumab was remarkable given that more than 40 % of patients crossed over from the control arm to
pembrolizumab after progression of the disease,» said Reck.
Not exact matches
Three patients had more serious autoimmune side effects, which are sometimes seen
after pembrolizumab treatment.
One patient was treated with the immunotherapy
pembrolizumab and now more than a year
after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases.
A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK - 3475 (
Pembrolizumab) as Adjuvant Therapy for Triple Receptor - Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN +)
After Neoadjuvant Chemotherapy
A Randomized, Double - Blinded, Phase II Study of Maintenance
Pembrolizumab versus Placebo
after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer